The global recombinant proteins market is projected to reach USD 1.7billion by 2026 from USD 1.0billion in 2021, at a CAGR of 9.8% during the forecast period. The market growth is primarily driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industryacademia collaborations, and the patent expiry of biologic products. Emerging markets in Asian countries and the rising focus on personalized medicine & protein therapeutics are other factors expected to offer strong growth opportunities for players in the recombinant proteins market. In contrast, the declining cost of recombinant proteins may restrict market growth to a certain extent
The pharmaceutical & biopharmaceutical companiessegmentis expected to dominate the market during the forecast period. Based on end users, the recombinant proteins market is segmented into pharmaceutical & biopharmaceutical companies, biotechnology companies, academic research institutes, contract research organizations, and other end users.Pharmaceutical & biopharmaceutical companies accounted for the largest share of the end-user market in 2020.
The large share of this segment is attributed to the high requirement of recombinant proteins for prognostic, predictive, or diagnostic identification and the quantification of biomarkers in drug discovery & development. Moreover, factors such as the patent expiration of blockbuster drugs and increasing investments in drug development support the growth of this segment.
Biologics segment will witness the highest growth intherecombinant proteins market.
Based on type, the drug discovery & development market is segmented into biologics, vaccines, and cell & gene therapy.Biologics accounted for the largest share of the drug discovery & development application for the recombinant proteins market and is expected to register the highest CAGR during the forecast period.
The large share of the biologics segment is attributed to the factors such as the increasing prevalence & incidence of target diseases, increasing research & development, and the strong development pipeline for recombinant protein-based biologics.
North America will dominate the market during the forecast period. Geographically, the recombinant proteins market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America accounted for the largest share of therecombinant proteins market.The large share of this region in the global market is attributed to the rising incidences of chronic & infectious diseases, increasing R&D spending, increasing research activities, favorable government funding, and the presence of key players in this region.
The primary interviews conducted for this report can be categorized as follows: • By Company Type -Tier 1: 36%, Tier 2: 45%,and Tier 3: 19% • By Designation - C-level:33%, D-level:40%, and Others:27% • By Region - North America:36%, Europe:28%, Asia Pacific:19%, and Rest of the World: 17%
List of Companies Profiled in the Report • Thermo Fisher Scientific, Inc. (US) • Miltenyi Biotech (Germany) • Sino Biological Inc. (China) • Merck KGaA (Germany) • Abcam plc (UK) • Biolegend (US) • Bio-Rad Laboratories, Inc. (US) • GenScript Biotech Corporation (China) • Enzo Life Sciences, Inc. (US) • BPS Bioscience, Inc. (US) • PeproTech, Inc. (US) • Proteintech Group, Inc. (US) • Abnova Corporation (Taiwan) • R&D Systems (US) • STEMCELL Technologies Inc (Canada) • RayBiotech Inc (US) • CellGenix GmbH (Germany) • ACROBiosystems (US) • ProSpec-TechnoGene Ltd. (Israel) • Neuromics (US) • RICHCORE LIFESCIENCES PVTLTD (India) • Icosagen AS (US) • ProteoGenix (France) • United States Biological (US) • StressMarq BiosciencesInc (Canada) • Aviva Systems Biology Corporation (US)
Research Coverage: This report provides a detailed picture of the global recombinant proteinsmarket.It aims at estimating the size and future growth potential of the market across different segments, such as product,application, end userand region.
The report also analyzes factors (such as drivers, restraints,and opportunities) affecting market growth.It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders.
The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total recombinant proteins market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers: • Market Penetration: Comprehensive information on recombinant proteins offered by the top 25 players in the recombinant proteins market. The report analyses the recombinant proteins market by product, application, end userand region. • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various recombinant proteins across key geographic regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market. • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the recombinant proteins market.
Our reports have been used by over 10K customers, including:
The global biologics CDMO market (henceforth, referred to as the market studied) was valued at USD 9.93 billion in 2020, and it is expected to reach USD 18.90 billion by 2026, registering a CAGR of 11.2% during 2021-2026 (henceforth, referred to as the forecast period).? - The global pharmaceutical industry is growing at an exponential...
“VENETOCLAX - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Follicular lymphoma in 7 Major Markets. A detailed picture of the VENETOCLAX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the...
206 pages •
By The Business Research Company
• Dec 2020
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market. Description: Where is the largest and fastest growing...
The microcarriers market is projected to reach USD 2.9 billion by 2026 from USD 1.7 billion in 2021, at a CAGR of 10.7% during the forecast period. Increasing use of single-use bioreactors for bioprocessing, rising investmnet in R&D for developemnt of vaccines and therapeutic protiens, and increasing government funding for cell and gene therapy. •...
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% during the forecast period. Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects...
243 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Biologics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
The microcarrier market is majorly driven by factors such as rising demand for cell-based vaccines and therapeutics, the rapid growth of biologics and biosimilar industry, and increasing R&D and availability of funding for cell therapy research. Many of the current biologics in the pipeline are targeting the indications, which are small-molecule...
703 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2021
Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to the analysis,...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
“Venetoclax - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Diabetic Macular Edema in 7 Major Markets. A detailed picture of the Venetoclax in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.